Christopher Rowan, MD
Cardiovascular Disease · Reno, NVNPI 1477783264
Payments from drug & device makers
Across 321 payments — averaging $871.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$175K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$31K
- Daiichi Sankyo Inc.$26K
- Amgen$24K
- AstraZeneca$12K
- E.r. Squibb & Sons, L.L.C.$7K
- plus $6K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 14 | $175,216 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 53 | $30,695 |
| Daiichi Sankyo Inc. | 16 | $25,782 |
| Amgen | 20 | $24,011 |
| AstraZeneca | 29 | $11,610 |
| E.r. Squibb & Sons, L.L.C. | 5 | $6,658 |
| Abbott | 22 | $1,645 |
| Novartis | 37 | $620 |
| United Therapeutics Corporation | 21 | $508 |
| Actelion Pharmaceuticals US, Inc. | 18 | $446 |
| Bayer | 11 | $224 |
| Medtronic | 6 | $209 |
| Scpharmaceuticals Inc. | 8 | $207 |
| Philips North America LLC | 5 | $197 |
| Sanofi-aventis U.S. LLC | 2 | $186 |
| Johnson & Johnson(2 entities) | 9 | $153 |
| Pfizer | 4 | $153 |
| Abiomed | 6 | $147 |
| Edwards Lifesciences | 1 | $119 |
| Lexicon Pharmaceuticals, Inc. | 5 | $115 |
| Regeneron Healthcare Solutions, Inc. | 4 | $102 |
| Boehringer Ingelheim | 4 | $91 |
| Boston Scientific | 3 | $90 |
| Novo Nordisk | 4 | $85 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $53 |
| Alnylam Pharmaceuticals Inc. | 2 | $50 |
| Shockwave Medical, Inc | 2 | $46 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $32 |
| Biotronik Inc. | 1 | $27 |
| Tactile Systems Technology Inc | 1 | $25 |
| Atricure, Inc. | 1 | $23 |
| Irhythm Technologies, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Cardiva Medical, Inc. | 1 | $16 |
How this compares
$279,594 in reported general payments places this provider in the 95th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Reno
- Thomas-Duythuc ToReno$1.1M
- Joseph StevensonReno$363K
- Jay MasonReno$227K
- Devang DesaiReno$206K
- Ram ChallapalliReno$18K
- Anita KediaReno$9K
- Sridevi ChallapalliReno$8K
- Christopher WilsonReno$7K
- Ramprasad DandillayaLas Vegas$1.8M
- Chowdhury AhsanLas Vegas$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.